Collectionner le produit
Détails du produit
Synonyms
EGFRvIII
Source
PE-Labeled Human EGFRvIII, His Tag (EGI-HP2E3) is produced via site-specific conjugation of PE to Human EGFRvIII, His Tag under optimal conditions with a proprietary technology. Human EGFRvIII, His Tag is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Predicted N-terminus: Leu 25
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 42.2 kDa.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Application
Please note that this product is NOT compatible to streptavidin detection system.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Bioactivity-FACS
5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Epidermal growth factor receptor variant III
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
14 Détails
- Étape de développement la plus élevée：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
